Recruiting nowPhase 2Ages 14 Years to 70 Years
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Sponsor: Peking University People's Hospital · NCT06714383 on ClinicalTrials.gov ↗
Conditions studied
Osteosarcoma
What it tests
- Trilaciclibdrug
- Pirarubicindrug
- Lobaplatindrug
Where it's running1 site
1 international site
- Recruiting now
Peking University People's Hospital
Beijing, Beijing Municipality, China 100000
- Xin Sun(contact)+86 13810548607[email protected]
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: 1. Written informed consent signed; 2. Classic osteosarcoma confirmed by histopathology (high grade); 3. Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria; 4. Planned to receive neoadjuvant chemotherapy; 5. Measurable disease on CT by RECIST 1.1. 6. No antitumor system therapy received; 7. ECOG 0-1 8. Adequate organ function. 9. Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication. Exclusion Criteria: 1. History of malignancies of other type; 2. Allergic to study agent; 3. History of psychotropic substance abuse, alcohol or drug use; 4. The researchers considered inappropriate to join the study of any cause.
Updated 2024-12-03 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.